Verona Pharma plc Verona Pharma Appoints Dr. Desiree Luthman As Vice President Of Regulatory Affairs
June 22 2017 - 7:00AM
UK Regulatory
TIDMVRP TIDMVRP
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, today announces the appointment of Desiree
Luthman, DDS to the Company's executive team as Vice President,
Regulatory Affairs.
Dr. Luthman's experience during the last two decades includes a series
of roles leading regulatory affairs teams and strategies for
pharmaceutical products spanning from early development to post-approval
marketing. Throughout her career, Dr. Luthman has held regulatory
positions at large global pharmaceutical and biotechnology companies,
including Bristol-Meyers Squibb, Celgene and AstraZeneca. Prior to
joining Verona Pharma, Dr. Luthman directed regulatory activities
related to pulmonary disease at Sanofi and most recently led their
regulatory team through the FDA approval of dupilumab for atopic
dermatitis in the United States. Dr. Luthman earned her Doctor in Dental
Sciences from the Karolinska Institute in Sweden.
"We welcome Desiree to our growing Verona Pharma team," said Jan-Anders
Karlsson, PhD, CEO of Verona Pharma. "She has an accomplished track
record of working closely with the FDA and EMA on behalf of
international healthcare companies to achieve key regulatory milestones.
Her vast experience will be instrumental as we advance our regulatory
plans in the U.S. and Europe under her leadership in our effort to
deliver important new therapies to patients with respiratory diseases."
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercialising innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled,
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as
both a bronchodilator and an anti-inflammatory agent in a single
compound. Verona Pharma is developing RPL554 for the treatment of
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF),
and potentially asthma.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to,
statements regarding advancing our regulatory plans in the U.S. and
Europe and delivering new therapies to patients with respiratory
diseases.
These and other important factors under the caption "Risk Factors" in
our final prospectus filed with the Securities and Exchange Commission
("SEC") on April 28, 2017 relating to our Registration Statement on Form
F-1, and our other reports filed with the SEC, could cause actual
results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking statements at
some point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive info@veronapharma.com
Officer
FTI Consulting (UK Media and Investor Tel: +44 (0)20 3727 1000
Enquiries)
Simon Conway / Stephanie Cuthbert / veronapharma@fticonsulting.com
Natalie Garland-Collins
ICR, Inc. (US Media and Investor Enquiries)
Darcie Robinson Tel: +1 203 682 8379
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
June 22, 2017 07:00 ET (11:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024